HIPEC IN THE MANAGEMENT OF PERITONEAL CARCINOMATOSIS AND POTENTIAL MARKERS OF TREATMENT EFFICIENCY

Gastric cancer is a major health burden worldwide and is one of the leading causes of cancer deaths. The average 5-year survival rate is less than 20% and prognosis is very dramatic. It remains difficult to cure, primarily because most patients present with advanced. Peritoneal carcinomatosis (PC) is a stage IV of gastric cancer and has been regarded as a lethal condition, and these patients have considered receiving systemic chemotherapy or palliative therapy. However, no standard treatment for PC has been proposed and surgery or chemotherapy alone has no beneficial effect on survival. Currently many researchers have demonstrated progress in the use of cytoreductive surgery (CRS) in combination with heated intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis, but how HIPEC influence on the tumor growth or angiogenic factors, which are involved in metastases/recurrence of cancer not understandable. Therefore, in this review, we try to hypothesize that removal of the primary tumor combined with HIPEC procedure may improve survival in patient's though decrease the angiogenic and tumor growth factors (TGF, VEGF, EGFR).